Does the media refer more to VIR or COGT?

In the previous week, Vir Biotechnology and Vir Biotechnology both had 3 articles in the media. Vir Biotechnology's average media sentiment score of 1.81 beat Cogent Biosciences' score of 1.60 indicating that Vir Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cogent Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor SRRK or VIR?

In the previous week, Scholar Rock had 6 more articles in the media than Vir Biotechnology. MarketBeat recorded 9 mentions for Scholar Rock and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.81 beat Scholar Rock's score of 0.02 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor CGON or VIR?

In the previous week, CG Oncology had 1 more articles in the media than Vir Biotechnology. MarketBeat recorded 4 mentions for CG Oncology and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.81 beat CG Oncology's score of 0.96 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor TWST or VIR?

In the previous week, Twist Bioscience had 5 more articles in the media than Vir Biotechnology. MarketBeat recorded 8 mentions for Twist Bioscience and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.81 beat Twist Bioscience's score of 0.52 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Vir Biotechnology (VIR) Competitors

$9.72 -0.24 (-2.41%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$9.64 -0.09 (-0.87%)

As of 05:43 AM Eastern

Compare

VIR vs. COGT, SRRK, CNTA, CGON, and TWST

Should you buy Vir Biotechnology stock or one of its competitors? MarketBeat compares Vir Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vir Biotechnology include Cogent Biosciences (COGT), Scholar Rock (SRRK), Centessa Pharmaceuticals (CNTA), CG Oncology (CGON), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.

How does Vir Biotechnology compare to Cogent Biosciences?

Vir Biotechnology (NASDAQ:VIR) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Cogent Biosciences has lower revenue, but higher earnings than Vir Biotechnology. Cogent Biosciences is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	23.91	-$437.99M	-$3.13	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Vir Biotechnology has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

In the previous week, Vir Biotechnology and Vir Biotechnology both had 3 articles in the media. Vir Biotechnology's average media sentiment score of 1.81 beat Cogent Biosciences' score of 1.60 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cogent Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Vir Biotechnology currently has a consensus price target of $20.88, indicating a potential upside of 114.76%. Cogent Biosciences has a consensus price target of $43.73, indicating a potential upside of 16.73%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, research analysts clearly believe Vir Biotechnology is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Cogent Biosciences has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Cogent Biosciences	N/A	-104.27%	-54.64%

65.3% of Vir Biotechnology shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Vir Biotechnology beats Cogent Biosciences on 9 of the 15 factors compared between the two stocks.

How does Vir Biotechnology compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Scholar Rock has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

Scholar Rock has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Scholar Rock had 6 more articles in the media than Vir Biotechnology. MarketBeat recorded 9 mentions for Scholar Rock and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.81 beat Scholar Rock's score of 0.02 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Scholar Rock presently has a consensus target price of $56.00, suggesting a potential upside of 2.38%. Vir Biotechnology has a consensus target price of $20.88, suggesting a potential upside of 114.76%. Given Vir Biotechnology's higher probable upside, analysts clearly believe Vir Biotechnology is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Scholar Rock has higher earnings, but lower revenue than Vir Biotechnology. Scholar Rock is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Vir Biotechnology	$68.56M	23.91	-$437.99M	-$3.13	N/A

Summary

Scholar Rock and Vir Biotechnology tied by winning 8 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Centessa Pharmaceuticals?

Vir Biotechnology (NASDAQ:VIR) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Vir Biotechnology had 3 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 3 mentions for Vir Biotechnology and 0 mentions for Centessa Pharmaceuticals. Vir Biotechnology's average media sentiment score of 1.81 beat Centessa Pharmaceuticals' score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Vir Biotechnology	Very Positive
Centessa Pharmaceuticals	Neutral

Centessa Pharmaceuticals has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Centessa Pharmaceuticals has lower revenue, but higher earnings than Vir Biotechnology. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	23.91	-$437.99M	-$3.13	N/A
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

Vir Biotechnology has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

Vir Biotechnology presently has a consensus target price of $20.88, suggesting a potential upside of 114.76%. Centessa Pharmaceuticals has a consensus target price of $41.33, suggesting a potential upside of 2.06%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, equities analysts plainly believe Vir Biotechnology is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Summary

Vir Biotechnology beats Centessa Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

CG Oncology has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. CG Oncology's return on equity of -23.33% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

CG Oncology has higher earnings, but lower revenue than Vir Biotechnology. CG Oncology is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,582.80	-$160.99M	-$2.33	N/A
Vir Biotechnology	$68.56M	23.91	-$437.99M	-$3.13	N/A

CG Oncology has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

CG Oncology presently has a consensus target price of $81.73, suggesting a potential upside of 12.73%. Vir Biotechnology has a consensus target price of $20.88, suggesting a potential upside of 114.76%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, CG Oncology had 1 more articles in the media than Vir Biotechnology. MarketBeat recorded 4 mentions for CG Oncology and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.81 beat CG Oncology's score of 0.96 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

CG Oncology beats Vir Biotechnology on 9 of the 17 factors compared between the two stocks.

How does Vir Biotechnology compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

In the previous week, Twist Bioscience had 5 more articles in the media than Vir Biotechnology. MarketBeat recorded 8 mentions for Twist Bioscience and 3 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.81 beat Twist Bioscience's score of 0.52 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Twist Bioscience has a beta of 2.11, meaning that its stock price is 111% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

Twist Bioscience has higher revenue and earnings than Vir Biotechnology. Twist Bioscience is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	14.94	-$77.67M	-$1.33	N/A
Vir Biotechnology	$68.56M	23.91	-$437.99M	-$3.13	N/A

Twist Bioscience presently has a consensus price target of $84.30, suggesting a potential downside of 6.70%. Vir Biotechnology has a consensus price target of $20.88, suggesting a potential upside of 114.76%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Twist Bioscience has a net margin of -19.85% compared to Vir Biotechnology's net margin of -638.88%. Twist Bioscience's return on equity of -26.73% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

65.3% of Vir Biotechnology shares are held by institutional investors. 3.1% of Twist Bioscience shares are held by insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Twist Bioscience beats Vir Biotechnology on 10 of the 17 factors compared between the two stocks.

Get Vir Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIR vs. The Competition

Export

Metric	Vir Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.68B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-3.11	20.85	27.13	24.26
Price / Sales	23.91	314.01	589.11	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	1.77	8.49	10.77	6.29
Net Income	-$437.99M	$23.83M	$3.58B	$330.66M
7 Day Performance	-5.17%	-3.56%	-2.10%	-1.32%
1 Month Performance	12.89%	6.31%	3.29%	-0.64%
1 Year Performance	76.73%	48.30%	26.34%	19.08%

Vir Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIR Vir Biotechnology	2.658 of 5 stars	$9.72 -2.4%	$20.88 +114.8%	+72.0%	$1.68B	$68.56M	N/A	580	News Coverage Positive News
COGT Cogent Biosciences	2.1125 of 5 stars	$39.44 +1.9%	$43.73 +10.9%	+241.2%	$6.61B	N/A	N/A	80	Positive News
SRRK Scholar Rock	1.7123 of 5 stars	$55.36 +0.9%	$56.00 +1.2%	+46.1%	$6.58B	N/A	N/A	140	Gap Down
CNTA Centessa Pharmaceuticals	0.8267 of 5 stars	$40.50 flat	$41.33 +2.1%	N/A	$6.27B	N/A	N/A	200
CGON CG Oncology	2.8191 of 5 stars	$69.26 -1.6%	$81.73 +18.0%	+171.3%	$6.21B	$4.04M	N/A	61

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIR) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vir Biotechnology (VIR) Competitors

VIR vs. COGT, SRRK, CNTA, CGON, and TWST

How does Vir Biotechnology compare to Cogent Biosciences?

Summary

How does Vir Biotechnology compare to Scholar Rock?

Summary

How does Vir Biotechnology compare to Centessa Pharmaceuticals?

Summary

How does Vir Biotechnology compare to CG Oncology?

Summary

How does Vir Biotechnology compare to Twist Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vir Biotechnology (VIR) Competitors

VIR vs. COGT, SRRK, CNTA, CGON, and TWST

How does Vir Biotechnology compare to Cogent Biosciences?

Which has better valuation and earnings, VIR or COGT?

Which has more risk & volatility, VIR or COGT?

Does the media refer more to VIR or COGT?

Do analysts rate VIR or COGT?

Is VIR or COGT more profitable?

Do institutionals and insiders have more ownership in VIR or COGT?

Summary

How does Vir Biotechnology compare to Scholar Rock?

Is SRRK or VIR more profitable?

Which has more risk & volatility, SRRK or VIR?

Do institutionals and insiders hold more shares of SRRK or VIR?

Does the media favor SRRK or VIR?

Do analysts recommend SRRK or VIR?

Which has higher valuation and earnings, SRRK or VIR?

Summary

How does Vir Biotechnology compare to Centessa Pharmaceuticals?

Do insiders and institutionals hold more shares of VIR or CNTA?

Does the media favor VIR or CNTA?

Is VIR or CNTA more profitable?

Which has better earnings & valuation, VIR or CNTA?

Which has more risk and volatility, VIR or CNTA?

Do analysts rate VIR or CNTA?

Summary

How does Vir Biotechnology compare to CG Oncology?

Is CGON or VIR more profitable?

Which has higher earnings & valuation, CGON or VIR?

Which has more volatility and risk, CGON or VIR?

Do analysts recommend CGON or VIR?

Do institutionals and insiders hold more shares of CGON or VIR?

Does the media favor CGON or VIR?

Summary

How does Vir Biotechnology compare to Twist Bioscience?

Does the media favor TWST or VIR?

Which has more volatility & risk, TWST or VIR?

Which has better valuation & earnings, TWST or VIR?

Do analysts rate TWST or VIR?

Is TWST or VIR more profitable?

Do insiders and institutionals have more ownership in TWST or VIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIR vs. The Competition

Vir Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools